Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen. Fulcrum had planned to enter a registrational trial for ...
June 2, 2026 07:21 AM EDT StartupsR&D Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit Kyle LaHucik Biotech Correspondent Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen. Fulcrum had Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that